Research
Hormonal
Tirzepatide and cagrilintide-semaglutide are promising agents for adjunctive pharmacological management of weight gain in SMI.
Practitioners should consider these new agents as potential options for managing weight gain in SMI patients.
StrongSupportsmedium confidence
This review identified tirzepatide and cagrilintide-semaglutide among others as promising agents for adjunctive pharmacological management of weight gain.
Why this rating
The claim is based on emerging research findings.
Source
Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness – a narrative review
Riddhita De et al. · Expert Opinion on Pharmacotherapy · 2023
DOI 10.1080/14656566.2023.2254698
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →